Cargando…

Tayside Screening For Cardiac Events (TASCFORCE) study: a prospective cardiovascular risk screening study

PURPOSE: Risk factor-based models struggle to accurately predict the development of cardiovascular disease (CVD) at the level of the individual. Ways of identifying people with low predicted risk who will develop CVD would allow stratified advice and support informed treatment decisions about the in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lambert, Matthew A, Houston, J Graeme, Littleford, Roberta, Fitton, Catherine A, Struthers, Allan, Sullivan, Frank, Gandy, Stephen, Belch, Jill J F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594527/
https://www.ncbi.nlm.nih.gov/pubmed/36270757
http://dx.doi.org/10.1136/bmjopen-2022-063594
_version_ 1784815441331355648
author Lambert, Matthew A
Houston, J Graeme
Littleford, Roberta
Fitton, Catherine A
Struthers, Allan
Sullivan, Frank
Gandy, Stephen
Belch, Jill J F
author_facet Lambert, Matthew A
Houston, J Graeme
Littleford, Roberta
Fitton, Catherine A
Struthers, Allan
Sullivan, Frank
Gandy, Stephen
Belch, Jill J F
author_sort Lambert, Matthew A
collection PubMed
description PURPOSE: Risk factor-based models struggle to accurately predict the development of cardiovascular disease (CVD) at the level of the individual. Ways of identifying people with low predicted risk who will develop CVD would allow stratified advice and support informed treatment decisions about the initiation or adjustment of preventive medication, and this is the aim of this prospective cohort study. PARTICIPANTS: The Tayside Screening for Cardiac Events (TASCFORCE) study recruited men and women aged≥40 years, free from known CVD, with a predicted 10-year risk of coronary heart disease<20%. If B-type natriuretic peptide (BNP) was greater than their gender median, participants were offered a whole-body contrast-enhanced MRI (WBCE-MRI) scan (cardiac imaging, whole-body angiography to determine left ventricular parameters, delayed gadolinium enhancement, atheroma burden). Blood, including DNA, was stored for future biomarker assays. Participants are being followed up using electronic record-linkage cardiovascular outcomes. FINDINGS TO DATE: 4423 (1740, 39.3% men) were recruited. Mean age was 52.3 years with a median BNP of 7.50 ng/L and 15.30 ng/L for men and women, respectively. 602 had a predicted 10-year risk of 10%–19.9%, with the remainder<10%. Age, female sex, ex-smoking status, lower heart rate, higher high-density lipoprotein and lower total cholesterol were independently associated with higher log10 BNP levels. Mean left ventricular mass was 129.2 g and 87.0 g in men and women, respectively. FUTURE PLANS: The TASCFORCE study is investigating the ability of a screening programme, using BNP and WBCE-MRI, at the time of enrolment, to evaluate prediction of CVD in a population at low/intermediate risk. Blood stored for future biomarker analyses will allow testing/development of novel biomarkers. We believe this could be a new UK Framingham study allowing study for many years to come. CLINICAL TRIAL REGISTRATION: ISRCTN38976321.
format Online
Article
Text
id pubmed-9594527
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-95945272022-10-26 Tayside Screening For Cardiac Events (TASCFORCE) study: a prospective cardiovascular risk screening study Lambert, Matthew A Houston, J Graeme Littleford, Roberta Fitton, Catherine A Struthers, Allan Sullivan, Frank Gandy, Stephen Belch, Jill J F BMJ Open Cardiovascular Medicine PURPOSE: Risk factor-based models struggle to accurately predict the development of cardiovascular disease (CVD) at the level of the individual. Ways of identifying people with low predicted risk who will develop CVD would allow stratified advice and support informed treatment decisions about the initiation or adjustment of preventive medication, and this is the aim of this prospective cohort study. PARTICIPANTS: The Tayside Screening for Cardiac Events (TASCFORCE) study recruited men and women aged≥40 years, free from known CVD, with a predicted 10-year risk of coronary heart disease<20%. If B-type natriuretic peptide (BNP) was greater than their gender median, participants were offered a whole-body contrast-enhanced MRI (WBCE-MRI) scan (cardiac imaging, whole-body angiography to determine left ventricular parameters, delayed gadolinium enhancement, atheroma burden). Blood, including DNA, was stored for future biomarker assays. Participants are being followed up using electronic record-linkage cardiovascular outcomes. FINDINGS TO DATE: 4423 (1740, 39.3% men) were recruited. Mean age was 52.3 years with a median BNP of 7.50 ng/L and 15.30 ng/L for men and women, respectively. 602 had a predicted 10-year risk of 10%–19.9%, with the remainder<10%. Age, female sex, ex-smoking status, lower heart rate, higher high-density lipoprotein and lower total cholesterol were independently associated with higher log10 BNP levels. Mean left ventricular mass was 129.2 g and 87.0 g in men and women, respectively. FUTURE PLANS: The TASCFORCE study is investigating the ability of a screening programme, using BNP and WBCE-MRI, at the time of enrolment, to evaluate prediction of CVD in a population at low/intermediate risk. Blood stored for future biomarker analyses will allow testing/development of novel biomarkers. We believe this could be a new UK Framingham study allowing study for many years to come. CLINICAL TRIAL REGISTRATION: ISRCTN38976321. BMJ Publishing Group 2022-10-21 /pmc/articles/PMC9594527/ /pubmed/36270757 http://dx.doi.org/10.1136/bmjopen-2022-063594 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Cardiovascular Medicine
Lambert, Matthew A
Houston, J Graeme
Littleford, Roberta
Fitton, Catherine A
Struthers, Allan
Sullivan, Frank
Gandy, Stephen
Belch, Jill J F
Tayside Screening For Cardiac Events (TASCFORCE) study: a prospective cardiovascular risk screening study
title Tayside Screening For Cardiac Events (TASCFORCE) study: a prospective cardiovascular risk screening study
title_full Tayside Screening For Cardiac Events (TASCFORCE) study: a prospective cardiovascular risk screening study
title_fullStr Tayside Screening For Cardiac Events (TASCFORCE) study: a prospective cardiovascular risk screening study
title_full_unstemmed Tayside Screening For Cardiac Events (TASCFORCE) study: a prospective cardiovascular risk screening study
title_short Tayside Screening For Cardiac Events (TASCFORCE) study: a prospective cardiovascular risk screening study
title_sort tayside screening for cardiac events (tascforce) study: a prospective cardiovascular risk screening study
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594527/
https://www.ncbi.nlm.nih.gov/pubmed/36270757
http://dx.doi.org/10.1136/bmjopen-2022-063594
work_keys_str_mv AT lambertmatthewa taysidescreeningforcardiaceventstascforcestudyaprospectivecardiovascularriskscreeningstudy
AT houstonjgraeme taysidescreeningforcardiaceventstascforcestudyaprospectivecardiovascularriskscreeningstudy
AT littlefordroberta taysidescreeningforcardiaceventstascforcestudyaprospectivecardiovascularriskscreeningstudy
AT fittoncatherinea taysidescreeningforcardiaceventstascforcestudyaprospectivecardiovascularriskscreeningstudy
AT struthersallan taysidescreeningforcardiaceventstascforcestudyaprospectivecardiovascularriskscreeningstudy
AT sullivanfrank taysidescreeningforcardiaceventstascforcestudyaprospectivecardiovascularriskscreeningstudy
AT gandystephen taysidescreeningforcardiaceventstascforcestudyaprospectivecardiovascularriskscreeningstudy
AT belchjilljf taysidescreeningforcardiaceventstascforcestudyaprospectivecardiovascularriskscreeningstudy